Clinical Trial Update: Phase II Study of Best Support Care (BSC) Plus ZD6474(Vandetanib) in Patients With Inoperable Hepatocellular Carcinoma (HCC) [Phase 2]

View source ↗

Summary

Phase II trial evaluating vandetanib plus best supportive care in inoperable hepatocellular carcinoma has completed, with results posted in 2012.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Vandetanib (vandetanib)

Snippet

Sponsor: Genzyme, a Sanofi Company | Conditions: Carcinoma, Hepatocellular | Phase 2 | Status: COMPLETED | Results posted: 2012-07-17